2024-10-22 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis Report

This report provides an analysis of Thermo Fisher Scientific Inc. (TMO) stock based on the provided data.

**1. Performance vs. S&P 500:**

Thermo Fisher Scientific Inc. (TMO) is a leading provider of scientific instrumentation, reagents, consumables, and software for research, diagnostics, and production.

* **Cumulative Return:** TMO has delivered a cumulative return of 237.37%, significantly outperforming the S&P 500 (VOO) which has returned 136.39%.
* **Outperformance:** TMO's outperformance is evident with a current price difference of 100.98%. This puts TMO in the 46.82% percentile relative to its historical range compared to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $590.44
* **5-day Moving Average:** $595.66 
* **20-day Moving Average:** $602.31 
* **60-day Moving Average:** $607.02

The stock price is currently below its 5, 20, and 60-day moving averages, indicating a recent downward trend.

**3. Technical Indicators:**

* **RSI:** 34.98 - This suggests that TMO is currently in oversold territory.
* **PPO:** -0.15 - A negative PPO indicates a bearish trend.
* **Delta_Previous_Relative_Divergence:** -6.95 - This indicates a short-term downward trend.
* **Expected Return:** 36.7% - This suggests a potential long-term (2 years or more) outperformance compared to the S&P 500, assuming continued investment.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | 4.05 | 10.54 B$ |
| 2024-05-03 | 3.47 | 10.35 B$ |
| 2023-11-03 | 4.44 | 10.57 B$ |
| 2023-08-04 | 3.53 | 10.69 B$ |
| 2024-08-02 | 3.53 | 10.69 B$ |

The latest earnings report (2024-08-02) shows that TMO exceeded analysts' expectations, reporting EPS of 4.05 against an estimated EPS of 3.85. Revenue came in at 10.54 Billion dollars, also surpassing expectations. 

**5. News and Recent Issues:**

Recent market outlook for TMO is mixed. While analysts acknowledge the strong performance and solid fundamentals of the company, some are cautious due to potential economic uncertainties. The company's strong position in the growing diagnostics and life sciences market remains a key driver for future growth. 

According to FINBOLD, analysts generally maintain a positive view of TMO, with most rating it as a "Buy" or "Strong Buy." The analysts highlight the company's robust earnings, strong market position, and commitment to research and development as key strengths. However, they also mention that a potential recession and regulatory uncertainties could pose challenges.

**6.  Overall Analysis:**

TMO has significantly outperformed the S&P 500 in terms of cumulative return. The company's recent earnings have been strong, exceeding analysts' expectations. However, recent price movements suggest a short-term downward trend, supported by technical indicators like RSI and PPO. Despite the recent downward trend, the long-term outlook for TMO remains positive, driven by its leading market position, commitment to innovation, and potential for continued growth in the diagnostics and life sciences market.

**7. Conclusion:**

Thermo Fisher Scientific Inc. (TMO) is a solid company with strong fundamentals and a promising future. While the stock is currently experiencing some short-term weakness, its long-term potential remains attractive. Investors who are looking for a high-quality company with growth potential should consider TMO for their portfolio. However, given the current market uncertainty, it is important to monitor the company's progress closely. 
